[go: up one dir, main page]

AR065420A1 - ANTI-IL-23 P19 ENGINEERING ANTIBODIES - Google Patents

ANTI-IL-23 P19 ENGINEERING ANTIBODIES

Info

Publication number
AR065420A1
AR065420A1 ARP080100715A ARP080100715A AR065420A1 AR 065420 A1 AR065420 A1 AR 065420A1 AR P080100715 A ARP080100715 A AR P080100715A AR P080100715 A ARP080100715 A AR P080100715A AR 065420 A1 AR065420 A1 AR 065420A1
Authority
AR
Argentina
Prior art keywords
vector
human
nucleic acid
variable domain
light chain
Prior art date
Application number
ARP080100715A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR065420A1 publication Critical patent/AR065420A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)

Abstract

Se proveen anticuerpos de ingeniería para IL-23p19 humana, así como también usos de los mismos, por ejemplo en el tratamiento de trastornos inflamatorios, autoinmunes, y proliferativos. Asimismo se provee un ácido nucleico que codifica al menos undominio variable de cadena liviana o de cadena pesada del compuesto de union a IL-23p19, un vector que comprende el ácido nucleico, una célula que comprende el vector y un método de produccion del polipéptido cultivado en la célula anteriormentemencionada. Reivindicacion 1: Un compuesto de union que se une a IL-23p19 humana que comprende un dominio variable de cadena liviana de anticuerpo, o un fragmento de union a antígeno del mismo, que incluye una o más secuencias de CDR seleccionadasdel grupo integrado por los NOs ID SEC: 32-46.Engineering antibodies to human IL-23p19 are provided, as well as uses thereof, for example in the treatment of inflammatory, autoimmune, and proliferative disorders. A nucleic acid is also provided that encodes at least one light chain or heavy chain variable domain of the IL-23p19 binding compound, a vector comprising the nucleic acid, a cell comprising the vector and a method of producing the cultured polypeptide. in the cell mentioned above. Claim 1: A binding compound that binds to human IL-23p19 comprising an antibody light chain variable domain, or an antigen binding fragment thereof, that includes one or more CDR sequences selected from the group consisting of NOs SEC ID: 32-46.

ARP080100715A 2007-02-23 2008-02-21 ANTI-IL-23 P19 ENGINEERING ANTIBODIES AR065420A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89140907P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR065420A1 true AR065420A1 (en) 2009-06-03

Family

ID=39592753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100715A AR065420A1 (en) 2007-02-23 2008-02-21 ANTI-IL-23 P19 ENGINEERING ANTIBODIES

Country Status (30)

Country Link
US (3) US8293883B2 (en)
EP (2) EP2059534B1 (en)
JP (5) JP2010518856A (en)
KR (1) KR101520110B1 (en)
CN (1) CN101687925B (en)
AR (1) AR065420A1 (en)
AT (1) ATE554791T1 (en)
AU (1) AU2008218968B2 (en)
BR (1) BRPI0807710B1 (en)
CA (1) CA2678749C (en)
CY (3) CY1112912T1 (en)
DK (2) DK2426144T3 (en)
ES (2) ES2708988T3 (en)
FR (1) FR18C1051I2 (en)
HR (2) HRP20120611T1 (en)
HU (2) HUE042172T2 (en)
IL (1) IL200560A (en)
LT (2) LT2426144T (en)
LU (1) LUC00092I2 (en)
MX (1) MX2009009079A (en)
NL (1) NL300959I2 (en)
NO (1) NO2018040I1 (en)
NZ (1) NZ579158A (en)
PL (2) PL2059534T3 (en)
PT (2) PT2059534E (en)
RS (2) RS52345B (en)
SI (2) SI2059534T1 (en)
TR (1) TR201821029T4 (en)
WO (1) WO2008103432A1 (en)
ZA (1) ZA200906224B (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2410406T3 (en) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, procedures and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MY157796A (en) 2006-06-08 2016-07-29 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (en) 2007-02-12 2014-02-21 Merck Sharp & Dohme Use of il-23 antagonists for treatment of infection
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
ATE554791T1 (en) * 2007-02-23 2012-05-15 Schering Corp GENETICALLY ENGINEERED ANTI-IL-23P19 ANTIBODIES
ES2719728T3 (en) 2007-09-04 2019-07-12 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a pharmacological target to produce drugs and biological agents
KR102339457B1 (en) 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
CA2708532C (en) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
CN101939025B (en) 2007-12-05 2015-03-25 中外制药株式会社 Therapeutic agent for pruritus
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012507723A (en) * 2008-11-03 2012-03-29 シェーリング コーポレイション Inflammatory bowel disease biomarkers and related treatment methods
JP5139517B2 (en) * 2008-12-05 2013-02-06 中外製薬株式会社 Anti-NR10 antibody and use thereof
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
WO2010071800A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
KR101048593B1 (en) 2009-02-27 2011-07-12 씨제이제일제당 (주) How to increase methionine production using a mixture of methylmercaptan and dimethylsulfide
KR101164711B1 (en) 2009-02-27 2012-07-11 씨제이제일제당 (주) A method of enhancing the methionine solubility using mineral addition and acid treatment
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107109A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US8283152B2 (en) 2009-08-28 2012-10-09 Cj Cheiljedang Corporation Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US8609396B2 (en) 2009-08-28 2013-12-17 Cj Cheiljedang Corporation Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
EP2480251B1 (en) * 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Proteins bind to human IL-23 antigens
WO2011103105A1 (en) * 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
BR112013013354A2 (en) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly
CA2822775A1 (en) 2011-01-04 2012-07-12 Charite Universitatsmedizin Berlin Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
EP2756093A4 (en) 2012-02-01 2015-07-01 Compugen Ltd C10RF32 ANTIBODIES AND USES THEREOF FOR TREATING CANCER
WO2013165791A1 (en) * 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
CZ304514B6 (en) 2012-11-23 2014-06-11 Biotechnologický Ústav Av Čr, V.V.I. Polypeptides intended for the treatment of autoimmune diseases based on blocking of human IL-23 cytokine receptor
UA117466C2 (en) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
US20150307606A1 (en) * 2012-12-13 2015-10-29 Ashwin Basarkar Lyophilized spherical pellets of anti-il-23 antibodies
TWI636063B (en) * 2013-03-08 2018-09-21 美國禮來大藥廠 Antibody that binds IL-23
US20160060337A1 (en) 2013-03-15 2016-03-03 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
AU2014228553B2 (en) 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
US10774119B2 (en) 2014-05-22 2020-09-15 Pieris Pharmaceuticals Gmbh Specific-binding polypeptides and uses thereof
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
US20160355589A1 (en) * 2014-08-19 2016-12-08 Merck Sharp & Dohme Corp. Anti-tigit antibodies
US10059763B2 (en) 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
AR102417A1 (en) 2014-11-05 2017-03-01 Lilly Co Eli ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods for treating inflammatory diseases
WO2016167263A1 (en) 2015-04-14 2016-10-20 中外製薬株式会社 Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CA2977534A1 (en) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
JP5954916B1 (en) 2015-04-14 2016-07-20 中外製薬株式会社 A pharmaceutical composition for preventing and / or treating atopic dermatitis, comprising an IL-31 antagonist as an active ingredient
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN116672446A (en) 2015-09-17 2023-09-01 美国安进公司 Predicting clinical response of IL23 antagonists using IL23 pathway biomarkers
TWI811716B (en) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 Methods of treating inflammatory diseases
BR112018012626A2 (en) 2015-12-22 2018-12-04 Amgen Inc ccl20 as a predictor of clinical response to il23 antagonists
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN115925790A (en) 2016-03-23 2023-04-07 领导医疗有限公司 Methods for synthesizing alpha 4 beta 7 peptide antagonists
AU2017250583A1 (en) 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
JP2019530707A (en) 2016-10-10 2019-10-24 セレラント セラピューティクス インコーポレイテッド Isoquinolidinobenzodiazepine (IQB) -1 (chloromethyl) -2,3-dihydro-1H-benzo [E] indole (CBI) dimer
EP3526252A2 (en) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Methods of treating diseases with il-23a antibody
CA3084459A1 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
WO2018071910A2 (en) * 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
TWI744617B (en) 2018-03-30 2021-11-01 美商美國禮來大藥廠 Methods of treating ulcerative colitis
SG11202100185VA (en) 2018-07-13 2021-02-25 Astrazeneca Collaboration Ventures Llc Treating ulcerative colitis with brazikumab
KR20210089215A (en) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
JP7517999B2 (en) * 2018-11-27 2024-07-17 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド Anti-IL-23p19 antibodies and uses thereof
EP3952993B1 (en) 2019-04-12 2025-01-08 Almirall S.A. Method of treating fumaric acid ester-resistant plaque psoriasis
CA3143604A1 (en) * 2019-04-15 2020-10-22 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with psoriatic arthritis
KR20220044277A (en) 2019-07-10 2022-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 Peptide inhibitors of interleukin-23 receptors and their use for treating inflammatory diseases
WO2021100794A1 (en) 2019-11-20 2021-05-27 中外製薬株式会社 Antibody-containing preparation
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12442001B2 (en) 2020-04-03 2025-10-14 Medrx Co., Ltd. Double stranded RNA specifically inhibiting expression of IL-23 and pharmaceutical composition comprising same
KR102481026B1 (en) * 2020-04-22 2022-12-22 한양대학교 산학협력단 Pharmaceutical composition for preventing or treating chemotherapy-induced peripheral neuropathy comprising the antibody of interleukin 23
CN112807428B (en) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 Pharmaceutical composition comprising anti-human interleukin 23 monoclonal antibody
TW202428304A (en) 2020-09-10 2024-07-16 美商美國禮來大藥廠 Therapeutic antibody formulations
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV Compositions of peptide inhibitors of interleukin-23 receptor
EP4347018A1 (en) 2021-05-28 2024-04-10 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
JP2024525732A (en) 2021-07-14 2024-07-12 ヤンセン バイオテツク，インコーポレーテツド Lipidated peptide inhibitors of the interleukin-23 receptor
EP4409298A1 (en) 2021-09-30 2024-08-07 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN117916273A (en) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 Anti-IL 23 antibody fusion proteins and uses
AU2023211042A1 (en) * 2022-01-25 2024-08-08 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with plaque psoriasis of the scalp
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
AU2024224464A1 (en) 2023-02-22 2025-08-14 Eli Lilly And Company Regulation of genes in ulcerative colitis and the uses thereof
WO2024241295A1 (en) 2023-05-25 2024-11-28 Sun Pharmaceutical Industries Limited Methods and compositions for treating plaque psoriasis
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025109545A1 (en) 2023-11-23 2025-05-30 Sun Pharmaceutical Industries Limited Methods for producing recombinant proteins
US20250228864A1 (en) 2023-11-29 2025-07-17 Gilead Sciences, Inc. Therapies for the treatment of inflammatory bowel disease
WO2025120601A1 (en) 2023-12-06 2025-06-12 Sun Pharmaceutical Industries Limited Methods and compositions for treating nail psoriasis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
ATE102631T1 (en) 1988-11-11 1994-03-15 Medical Res Council CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69330523D1 (en) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru IMMUNOGLOBULINE WITHOUT LIGHT CHAINS
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (en) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd NEW CYTOKINIC PROTEIN
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
WO2000053631A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
MXPA05004512A (en) 2002-10-30 2005-07-26 Genentech Inc Inhibition of il-17 production.
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
JP4605798B2 (en) 2003-03-10 2011-01-05 シェーリング コーポレイション IL-23 agonists and IL-23 antagonists; use of related reagents
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1697417A2 (en) 2003-11-07 2006-09-06 Curagen Corporation Antibodies against secretory leukocyte protease inhibitor
AR046833A1 (en) 2003-11-10 2005-12-28 Schering Corp ANTI-INTERLEUQUINA ANTIBODIES-10
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
ES2410406T3 (en) * 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, procedures and uses
EP1937721B1 (en) * 2005-08-25 2010-07-28 Eli Lilly And Company Anti-il-23 antibodies
HUE032131T2 (en) * 2005-08-31 2017-09-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
EP2064242A1 (en) * 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
ATE554791T1 (en) 2007-02-23 2012-05-15 Schering Corp GENETICALLY ENGINEERED ANTI-IL-23P19 ANTIBODIES
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
AR068723A1 (en) 2007-10-05 2009-12-02 Glaxo Group Ltd PROTEIN THAT JOINS ANTIGENS THAT JOINS HUMAN IL-23 AND ITS USES
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same

Also Published As

Publication number Publication date
JP2012228259A (en) 2012-11-22
HRP20120611T1 (en) 2012-10-31
US9809648B2 (en) 2017-11-07
EP2426144B1 (en) 2018-10-31
IL200560A (en) 2013-11-28
DK2059534T3 (en) 2012-08-06
WO2008103432A1 (en) 2008-08-28
CY2019004I1 (en) 2019-11-27
KR101520110B1 (en) 2015-05-18
KR20090114459A (en) 2009-11-03
SI2059534T1 (en) 2012-08-31
NL300959I2 (en) 2019-01-15
MX2009009079A (en) 2009-08-31
CY2019004I2 (en) 2019-11-27
EP2426144A1 (en) 2012-03-07
JP2012135319A (en) 2012-07-19
HUE042172T2 (en) 2019-06-28
PT2426144T (en) 2019-02-06
US8404813B2 (en) 2013-03-26
BRPI0807710B1 (en) 2021-12-14
PL2426144T3 (en) 2019-05-31
LTPA2018015I1 (en) 2019-01-10
JP2017060482A (en) 2017-03-30
NZ579158A (en) 2012-01-12
PT2059534E (en) 2012-07-17
TR201821029T4 (en) 2019-01-21
LT2426144T (en) 2018-12-10
NO2018040I1 (en) 2018-11-15
CA2678749C (en) 2018-03-13
AU2008218968B2 (en) 2013-10-17
BRPI0807710A2 (en) 2014-05-27
DK2426144T3 (en) 2019-01-07
US20110142853A1 (en) 2011-06-16
ES2708988T3 (en) 2019-04-12
LTC2059534I2 (en) 2019-10-10
BRPI0807710A8 (en) 2016-02-10
LUC00092I2 (en) 2019-12-24
CN101687925B (en) 2012-10-31
US8293883B2 (en) 2012-10-23
LUC00092I1 (en) 2018-11-15
US20100272731A1 (en) 2010-10-28
ZA200906224B (en) 2010-07-28
US20130122009A1 (en) 2013-05-16
JP2014128278A (en) 2014-07-10
HUS1800045I1 (en) 2018-12-28
RS58098B1 (en) 2019-02-28
AU2008218968A1 (en) 2008-08-28
ES2388837T3 (en) 2012-10-19
JP5014521B2 (en) 2012-08-29
EP2059534A1 (en) 2009-05-20
HK1127864A1 (en) 2009-10-09
CN101687925A (en) 2010-03-31
HRP20182174T1 (en) 2019-02-22
RS52345B (en) 2012-12-31
PL2059534T3 (en) 2012-09-28
CY1112912T1 (en) 2016-04-13
CA2678749A1 (en) 2008-08-28
FR18C1051I2 (en) 2019-12-27
CY1121327T1 (en) 2020-05-29
FR18C1051I1 (en) 2019-02-15
EP2059534B1 (en) 2012-04-25
SI2426144T1 (en) 2019-02-28
ATE554791T1 (en) 2012-05-15
IL200560A0 (en) 2010-05-17
JP2010518856A (en) 2010-06-03
JP6054898B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
AR065420A1 (en) ANTI-IL-23 P19 ENGINEERING ANTIBODIES
AR065496A1 (en) ANTIBODIES ANTI- IL-23 R
CL2021001986A1 (en) Antibodies and chimeric antigen receptors specific for orphan receptor tyrosine kinase-like receptor 1 (ror1).
AR079336A1 (en) ANTAGONISTS OF THE PRO-PROTEIN CONVERTASE-SUBTILISINE / TYPE 9 QUEXINE (PCSK9)
AR096895A2 (en) ANTIBODY THAT Binds TO THE CYTOQUINE, THYMPIC STROMAL LYMPHOPOYETIN (TSLP)
EA201490677A1 (en) BONDING ANTIGEN CD27L PROTEINS
AR063090A1 (en) PROTEINS OF UNION TO THE ANTIGEN OF THE RECEIVER OF IL-17
EA201591113A1 (en) ANTIBODIES AGAINST ANTIGEN 2 BLOOD DENDRITIC CELLS AND THEIR APPLICATION
PE20141162A1 (en) ANTI-IL-23 ANTIBODIES
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
PE20091382A1 (en) ANTIBODIES THAT JOIN IL-4 AND / OR IL-13
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
CY1119925T1 (en) ANTI-CD40 ANTIBODIES, USES AND METHODS
AR109355A2 (en) OX40 HUMAN RECEIVER UNION MOLECULES
MX2020002076A (en) ANTIBODIES OF B7-H4 AND METHODS OF USING THEM.
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
EA201390453A1 (en) HUMAN ANTI-TAU ANTIBODIES
NZ706377A (en) Il-6 antagonists and uses thereof
EA201101516A1 (en) ANTIBODIES SPECIFIC FOR KADGERINA-17
PE20110225A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5
PE20141659A1 (en) ANTI-VGF SINGULAR VARIABLE DOMAINS FUSED WITH FC DOMAINS
CY1117702T1 (en) PROTEIN BINDED WITH ANTIGENO CAPABLE TO BIND WITH MODIFIED LAYER Lymphopoietin
MX2023000738A (en) ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR.
CL2011000632A1 (en) Humanized antibody interleukin-6 receptor (il-6); variable regions and heavy or light chains thereof; nucleotide sequence that encodes it; vector; host cell; Method of production; and pharmaceutical composition that comprises it.
AR091069A1 (en) PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER

Legal Events

Date Code Title Description
FG Grant, registration